Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 439

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 4
Chunk 439
---
 were not reached for the 26 efficacy evaluable patients in the follicular lymphoma cohort. For the MZL cohort of 16 efficacy evaluable patients, at median follow-up of 20.3 months, median DoR was not reached and median PFS was 26.8 months. Amdizalisib showed an acceptable safety profile and promising anti-tumor activity in relapsed/refractory lymphoma.
​

15. Immunology Collaboration with Inmagene
We have a strategic partnership with Inmagene to develop two novel drug candidates (IMG-004 and IMG-007) discovered by us for the potential treatment of multiple immunological diseases, with funding provided by Inmagene. We received shares representing approximately 7.5% of the shares in Inmagene (fully diluted) in July 2024, as consideration for Inmagene’s exclusive license to further develop, manufacture and commercialize these two drug candidates worldwide. On December 23, 2024, Inmagene and Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,”) announced that they had signed a merger agreement which the parties expect to close in mid-2025, subject to closing conditions. Following closing, we will have an interest in the Nasdaq-listed merged company. For more details on the collaboration arrangement, please see “—Our Collaborations—Inmagene.”

           ​              ​                            ​                            ​        ​        ​     ​     ​                    ​                     ​        ​     
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Treatment                     Patient Focus                                             Sites             Phase       Status/Plan                                NCT #      
IMG-007 (OX40 antibody)       Adults with moderate-to-severe atopic dermatitis          U.S. Canada       IIa         Full results IIb planned for Q1 2025       NCT05984784
IMG-007 (OX40 antibody)       Alopecia areata with 50% or greater scalp hair loss       U.S. Canada       IIa         Fully enrolled; results pending            NCT06060977
IMG-004 (BTK inhibitor)       Adult healthy volunteers                                  U.S.              I           Single ascending dose completed            NCT05349097
​
IMG-007, a novel antagonistic monoclonal antibody targeting the OX40 receptor with silenced antibody-dependent cell-mediated cytotoxicity function. OX40 is a costimulatory receptor, a member of the tumor necrosis factor receptor superfamily expressed predominantly on activated T cells. One